CL
AVNR

Croft-Leominster’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Croft-Leominster’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-70,200
Closed -$236K – 221
2013
Q4 		$236K Hold
70,200
– – 0.04% 159
2013
Q3 		$297K Hold
70,200
– – 0.05% 127
2013
Q2 		$323K Buy
+70,200
New +$241K 0.05% 121

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Croft-Leominster's AVNR Position: Q1 2014 in Review

Croft-Leominster sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2014, closing a stake of 70,200 shares — an estimated $236K sold.

Croft-Leominster first reported a position in AVNR in Q2 2013 and held it in 3 quarters. The position peaked at $323K in Q2 2013. 100 funds tracked by Wall St. Rank hold AVNR as of Q1 2014.

  • Croft-Leominster reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2014 after selling out during the quarter.
  • Croft-Leominster sold 70,200 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2014, an estimated $236K.
  • Croft-Leominster first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 3 quarters.
  • Croft-Leominster's AVANIR PHARMACEUTICALS, INC CL A position peaked at $323K in Q2 2013.
  • 100 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2014.

Based on Croft-Leominster's 13F filing for Q1 2014, filed 15 May 2014.